Payer Mix, Medicaid Timing, and Buyer Selectivity for Behavioral Health Owners in 2025 and 2026

If you own a behavioral health practice and you are thinking about a sale, three questions usually show up together. Are buyers still active. How hard will they look at your payer mix. What does Medicaid timing do to your story.

This page is different. It puts payer mix, Medicaid timing, and buyer selectivity in one place for an owner who has to decide what to do next.

What buyers are selecting for now

Buyers did not leave the market. They got choosier.

Mertz Taggart’s Q3 2025 Behavioral Health M&A Report counted 40 deals that quarter. That put 2025 on track for about 167 deals, versus about 100 a year before COVID. In that same report, Kevin Taggart said private equity still calls weekly, that strong companies can still get strong prices, and that deals get harder when the first buyer falls out.

Mertz Taggart’s Q4 2025 report said 2025 finished with 180 deals, versus 176 in 2024. Mental health made up 111 of those. Addiction made up 33, the lowest in six years in that tracker. Intellectual and developmental disabilities and autism made up 36. The report also said buyers are flying to quality, lenders are taking longer on receivables after Change Healthcare and Medicaid uncertainty, and federal scrutiny of private equity roll-ups sometimes pushes buyers to stay quiet about deals.

Capstone Partners’ July 2026 Behavioral Healthcare Services report counted 44 announced or completed deals year to date in 2026, roughly on pace with 2025. Capstone said buyers got highly selective. Private strategics rose to 61.4% of year-to-date 2026 deals in Capstone’s count, up from 37.8% in the prior-year period. Private equity add-ons fell 17.3% year over year in that same Capstone count.

TUSK Practice Sales’ Q3 2026 report said buyers looked harder at credentialing, service mix, growth, and payer mix. TUSK treated payer mix and service diversification as drivers of who gets valued well. Citing PitchBook, TUSK also said private equity deal counts across behavioral health and skilled care were on pace through mid-2026 to finish about 31.6% below 2025. TUSK noted that private equity trackers miss a lot of independent, nonprofit, and health-system deals.

What that means for you. Deals are still happening. A blank check is not. If your practice is clean, growing, and in-network with a durable payer mix, buyers still care. If receivables are messy, growth is thin, or the payer story is fragile, expect a harder path. For the wider 2025–2026 market overview on this site, see Behavioral Health M&A in 2025–2026.

Payer mix and Medicaid policy timing

Payer mix is not a footnote anymore. It is one of the first things a serious buyer underwrites.

Capstone’s July 2026 report calls Medicaid funding pressure under the One Big Beautiful Bill Act a major headwind. Capstone also notes that Medicaid is the largest national payer for mental health and addiction treatment. Capstone points to an American Psychiatric Association update that Medicaid funding could fall about 15% (about $1 trillion) over the next decade. Capstone points to Congressional Budget Office estimates of 11.8 million people losing coverage directly, plus about 3.1 million through other means. Capstone also points to KFF data that nearly one-third of the Medicaid expansion population across 40 states has a diagnosable mental health or substance use disorder. That raises the stakes for residential and addiction providers.

Capstone cites CMS guidance on Medicaid community-engagement rules, including exemptions for people actively in drug or alcohol treatment or recovery. Capstone says states and providers have until early January 2027 for full compliance. TUSK’s Q3 2026 report says Medicaid work requirements and six-month eligibility reviews begin January 1, 2027. TUSK treats that date as a patient-retention and diligence issue for owners who plan to go to market later in 2027.

HFMA, summarizing RAND Health on February 27, 2026, projects state Medicaid budgets fall by $664 billion from 2025 to 2034. Enrollment falls by about 7.6 million by 2034, about 10% of 2025 enrollment. HFMA ties most of that to work requirements, provider-tax limits, and six-month eligibility checks.

In Capstone’s Avesi Partners Q&A, that firm’s adult addiction thesis prioritizes commercial payers because Medicaid coverage and rates have been unstable for high-quality programs. FOCUS Investment Banking’s 2025 EBITDA multiples update lists diversified payer mix as a core valuation driver and flags Medicaid volatility especially for mental health and ABA. TUSK says inpatient and residential care carry the heaviest Medicaid concentration and saw the sharpest slowdown, while interventional psychiatry with little Medicaid exposure drew stronger interest.

What that means for you. Know your commercial, Medicaid, and out-of-network mix before the first buyer call. A Medicaid-heavy practice can still sell. The buyer set, the diligence, and the timing change. If you are aiming for a later-2027 process, January 1, 2027 is a date you should be ready to discuss. For deeper Medicaid and payer-mix pages already on this site, see Medicaid concentration risk and payer mix and valuation.

What buyers punish on payer mix

Buyers do not always walk away from Medicaid. They price the risk. They punish the story when they cannot see it clearly.

TUSK’s Q3 2026 report said payer mix and service diversification decide who looks attractive. Inpatient and residential providers, which carry the heaviest Medicaid concentration in that report, slowed the most. Interventional psychiatry with little Medicaid exposure drew more interest.

Capstone’s July 2026 report describes selective buyers and frames Medicaid funding pressure as a major headwind. In Capstone’s Avesi Partners Q&A, that firm prefers commercial payers for adult addiction work because Medicaid coverage and rates have been unstable.

Scope Research’s 2025 addiction and substance-use valuation work says in-network and commercial-heavy mix usually support higher multiples than out-of-network or Medicaid-heavy profiles. Out-of-network also brings reimbursement volatility.

FOCUS’s 2025 update calls diversified payer mix a core valuation driver and calls out Medicaid volatility for mental health and ABA underwriting.

Mertz Taggart’s Q4 2025 report describes a flight to quality. Lenders slowed deals to dig deeper into insurance receivables after Change Healthcare and Medicaid uncertainty.

On March 5, 2024, the FTC, Department of Justice, and HHS opened a joint inquiry into private equity and corporate healthcare deals. That inquiry explicitly includes behavioral health providers and deals that do not clear HSR thresholds. Even when a buyer still wants the practice, that scrutiny can slow announcements and closings.

What that means for you. Opaque payer mix hurts. Heavy out-of-network dependence hurts. Thin commercial coverage hurts when the buyer’s thesis needs it. Receivables that cannot prove collectability hurt. Medicaid itself is not an automatic kill. Unexplained Medicaid risk is.

What to fix before outreach

It is what the same outside sources already say buyers and lenders look at.

• Get your payer mix on one clear page: commercial, Medicaid, and out-of-network. TUSK and Capstone put that mix at the center of diligence and valuations.
• Know the January 1, 2027 Medicaid work-requirement and six-month eligibility timing from TUSK, and Capstone’s path to CMS full compliance. Be ready to show how census or coverage risk shows up in your books.
• Push toward in-network commercial contracts where you can. Scope says that mix usually supports higher multiples than out-of-network or Medicaid-heavy profiles.
• Clean up receivables and denials evidence. Mertz Taggart says lenders now want proof of collectability.
• Show that your services and growth are not one fragile line. TUSK says buyers look at service mix next to payer mix.

If you want the site’s existing readiness guide, use how to prepare a behavioral health practice for sale.

How to read a quoted multiple

A quoted multiple is not a law. It is someone’s published range for a certain kind of practice.

The numbers below come from named advisors. They move by practice type and by platform versus add-on. They are educational. They are not a guarantee. They are not a Behavioral Health Business Broker or DealStats average.

We did not find a public industry database that publishes one official private multiple for behavioral health practices. Use the named-advisor ranges below.

FOCUS Investment Banking, 2025 EBITDA Multiples Update (citing Scope Research and PitchBook generally)

FOCUS says those ranges vary by deal and are not a guarantee.

Capstone also cites the Universal Health Services–Talkspace announced deal at about $835 million enterprise value, about 3.0× EV/revenue and about 26.1× EV/EBITDA on a forward-looking basis. That is a strategic, tech-enabled deal. It is not a private outpatient clinic multiple.

If someone quotes a market multiple, ask three questions. Whose range is it. Which practice type. Platform or add-on. For practice-type ranges already on this site, see EBITDA multiples by practice type and 2026 multiples market data.

What this means if you are thinking about a sale

Buyers are still here. They buy quality, durable payer mix, and a growth story they can underwrite.

Payer mix and Medicaid timing belong in the first diligence conversation, not as a late surprise.

A quoted multiple is only useful when you know who published it and what it covers.

Sources

Outside sources cited on this page:

• Mertz Taggart Q3 2025 Behavioral Health M&A Report
• Mertz Taggart Q4 2025 Behavioral Health M&A Report
• Capstone Partners Behavioral Healthcare Services M&A Coverage Report, July 2026
• TUSK Practice Sales Q3 2026 Behavioral Health Market Report
• HFMA — OBBBA Medicaid cuts / state budget impact
• FTC / DOJ / HHS cross-government inquiry (March 2024)
• FOCUS Investment Banking — Behavioral Health EBITDA Multiples
• FOCUS Investment Banking — Behavioral Health Practice Valuation
• Scope Research — Addiction / SUD Valuation Multiples and M&A Trends 2025

Related pages on this site:

• Payer mix and valuation
• Medicaid concentration risk
• EBITDA multiples by practice type
• 2026 multiples market data
• Behavioral Health M&A in 2025–2026
• How to prepare a behavioral health practice for sale